Biopharma leaders condemn mob violence on Capitol Hill, looking to close Trump's chaotic chapter in American history
Some of the leading voices in biopharma have had a difficult time over the last 4 years watching Donald Trump march through American history with an often fractious view of the drug industry. Biopharma leaders and organizations have condemned the administration’s immigration policies and vehemently objected to Trump’s drug pricing proposals. But they also enjoyed the warm embrace of Trump’s Operation Warp Speed in a sprint to develop new vaccines and drugs for Covid-19, with heavy government subsidies, even if the president also accused Pfizer of dragging its feet on their application for an OK to get clear of voting day.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 148,300+ biopharma pros reading Endpoints daily — and it's free.